Nivolumab is one of the standard therapy for previously treated advanced non-small-cell lung cancer (NSCLC) [1] . Durable responses are observed in NSCLC patients treated with nivolumab, but there are fewer than half of patients who will benefit [1] .
Immunotherapy administration after radiotherapy may provide synergistic effects (i.e. abscopal effect) [2, 3] . However, it is unclear whether past radiotherapy especially to lung is predictive or not in NSCLC who receive immune checkpoint inhibitor.
We conducted a multicenter retrospective cohort study. We included consecutive patients treated with nivolumab between January 2016 and October 2016 after the second line systemic chemotherapy outside of a clinical trial. Variables were retrieved from the medical records before the administration of nivolumab. All variables were dichotomized based on previous study or median [4, 5] . Primary endpoint was progression-free survival (PFS) defined by response evaluation criteria in solid tumors (RECIST) 1.1. Two researchers evaluated the endpoint independently. Any disagreements were resolved by discussion. Cox proportional hazards models were used to assess the impact of pretreatment markers on PFS.
One hundred forty-six patients were included. Median observation period were 153 days. Patients characteristics were as follows: median age 69 years, female 36 (25%), never smoker 28 (19%), performance status <2 110 (75%), non-squamous histology 107 (73%). The main results are shown in Table 1 . No difference of progression free survival between those without past radiotherapy and received in past 6 months was noted [adjusted hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.37-1.14]. Ten patients (7%) suffered pneumonitis. Two patients received radiotherapy to the lung before one year. Eight patients did not received radiotherapy to the lung (risk ratio 1.34; 95% CI 0.30-5.90).
Past radiotherapy was not a predictive factor. Our study had limited sample size (146 patients with 112 events). Assuming a two-sided a of 0.05, the power to detect the HR of 0.65 was 0.63. So, the conclusion might change with the larger sample size. The results do not deny the additional effect of concurrent radiotherapy with immune checkpoint inhibitor in NSCLC. Further investigation of concurrent radiotherapy is warranted. 
